Pull incentives for antibiotics: Duke-Margolis PAVE policy paper and PBS Newshour segments

Dear All: 

We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this!

Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to the voices calling for new economic models for antibiotics.

First, the Duke-Margolis Center for Health Policy has released both a White Paper and a viewpoint paper in JAMA describing the elements of a Priority Antimicrobial Value and Entry (PAVE) Award proposal that could be a path for the diverse and complex US market to create such a model. PAVE combines a market entry reward with population-based payments from public and private payers that phase in over time.

Second, PBS Newshour is doing a Stopping Superbugs series in which their science and economic correspondents have collaborated to tell this story. The first three episodes are out:

2 Aug 2017: We are running out of effective antibiotics
3 Aug 2017: The financial barrier
4 Aug 2017: Is there an economic cure for the problem?

We have yet to turn any of this into concrete action, but steadily expanding the conversational echo chamber is a necessary prelude to such action. I’m looking forward to the rest of the PBS broadcasts, and then next up, I think, will be the output from DRIVE-AB in early September. Stay tuned!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

AI-based drug discovery: Chemical vs. drugs (Part 4)

Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the original report has a new paper about identification of a narrow-spectrum compound with activity vs. Acinetobacter baumannii. Here are the links you’ll

WHO-UNEP-FAO-OIE Youth Engagement Working Group on AMR: Apply now!

“Education is the most powerful weapon we can use to change the world…” — Nelson Mandela Dear All, Regular readers will know my interest in developing the ecosystem of people who will work to address AMR over time (e.g., this interview with the founder of the Future Leaders Against AMR, my strong support for the

Reports calling for Pull: US GAO, Global AMR R&D Hub

Dear All, Two important reports for your awareness this afternoon. First, the Global AMR R&D hub have responded to a request from the G7 Finance and Health Ministers to provide an update to their 2022 progress report in advance of upcoming G7 meetings. As background, recall that the Finance Ministers in 2021 (during the UK G7

High Watermark for Pull Incentives (and more): Reflections on an amazing week!

Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …

Scroll to Top